北京若生智能科技有限公司
Drug Database
AS

AS0-3B (AS03B1 / AS03B)

✓ Approved

GSK · 治疗药物

什么是 AS0-3B？

AS0-3B 是一种治疗药物，由GSK研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名AS03B1, AS03B
公司GSK
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, GSK

治疗适应症

AS0-3B 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedCrohn's & colitis 3602026-10-25

Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.

Long Millie M, Laharie David D, Rogler Gerhard G, Navabi Seyedehsan S et al.

Mirikizumab, an anti-interleukin-23p19 monoclonal antibody approved for ulcerative colitis (UC) and Crohn's disease, was evaluated in LUCENT-URGE (NCT05767021), a phase 3b, open-label study assessing its effect on bowel urgency (BU) through week (W)28 in adults with moderately-to-severely active UC, using novel BU measures and validated quality of life (QoL) instruments. Patients with UC experiencing BU (baseline severity ≥3 on the urgency numeric rating scale [UNRS]) received 300 mg mirikizumab intravenously at W0, W4, and W8, then 200 mg subcutaneously at W12 and every 4 weeks up to W24. Improvements in QoL and patient-reported outcomes were assessed from baseline to W12 and W28. Among 172 patients, 58.1% achieved clinically meaningful improvement (≥3-point reduction in UNRS), and 37.8% reached BU remission (rounded UNRS ≤ 1) by W28. Inflammatory Bowel Disease Questionnaire (IBDQ) scores improved by 56.4 points, with 52.3% of patients achieving IBDQ-remission (IBDQ ≥ 170) and 65.7% achieving IBDQ-response (≥16-point increase) at W28. Absorbent product use for BU dropped from 55.1% at baseline to 29.6% at W28. Patients reporting no sexual activity avoidance (SAA) due to UC symptoms rose from 21.1% to 51.4%. Activity impairment, Wexner Incontinence Score, and anxiety symptoms also showed improvements. The majority of mirikizumab-treated patients achieved clinically meaningful BU improvement over 28 weeks. In addition to QoL improvement, patients experienced reduced disruption of daily activities, with meaningful reductions in SAA and use of protective aids due to BU. Achieving BU remission or clinically meaningful improvement with mirikizumab was associated with improvements in patients' relevant UC symptoms and overall QoL.

PMID 42927097
阅读全文 →
PubMedThe Journal of organic chemistry2026-10-25

Copper-Catalyzed Regioselective Synthesis of Fluorescent Indazolo[2,3-a]quinazolines and Their Photophysical Studies.

Kumar Abhishek A, Choudhury Lokman H LH

A regioselective copper-catalyzed one-pot cyclization of 3-aminoindazoles with 2-bromobenzyl bromides has been developed under ligand-free conditions for the efficient synthesis of indazolo[2,3-a]quinazolines. This reaction proceeds through initial site-selective nucleophilic N-benzylation of the primary amine of 3-aminoindazole, followed by an Ullmann-type intramolecular C-N coupling and subsequent oxidative aromatization. This method has advantages of broad substrate scope, high functional group tolerance, and gram scalability. The synthesized compounds were characterized by spectroscopic techniques, and their photophysical properties were investigated by UV-visible and fluorescence spectroscopy. The synthesized indazole-fused quinazolines display good fluorescent properties, with quantum yields (ΦF) of up to 76% and a large Stokes shift of up to 163 nm. Product 3b also showed chemosensing properties toward picric acid.

PMID 42925080
阅读全文 →
PubMedWiadomosci lekarskie (Warsaw, Poland : 1960)2026-10-25

Gender-specific determinants of the cardiorespiratory system and energy supply for working capacity in sport dance athletes.

Soronovych Igor I, Diachenko Andrii A, Murzalieva Aizhan A, Ismailov Imetkul I et al.

Aim: To identify specific functional characteristics of male and female partners in the semi-finals and finals of the standard European program. Materials and Methods: Twenty-one professional standard European dance couples were assessed during semifinal and final performances; VO₂, VCO₂, VE, and lactate were measured using MetaMax 3B and Biosen+. To compare independent samples, the Mann-Whitney U test was applied; data are presented as mean, median, SD, min-max, Q1-Q3, and IQR. Results: No significant differences were found between SF and F in VO₂max, VO₂max/kg, VE, EqO₂, VCO₂, VCO₂/kg, or EqCO₂. A significant difference was observed for lactate (p<0.05). These findings indicate stable functional support across competitive rounds, while higher lactate values in the final reflect greater glycolytic load, particularly in female partners. Conclusions: In most dancers, in F SEP, there was found an increase in aerobic metabolism in partners and glycolytic capacity in female partners. The reactive properties of the cardiorespiratory system are reflected in the efficiency of oxygen consumption per unit of pulmonary ventilation (EqO2) and the stability of the respiratory compensation response to metabolic acidosis.

PMID 42922317
阅读全文 →
PubMedJournal of viral hepatitis2026-10-25

Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial.

Han Win Min WM, Solomon Sunil S, Wagner-Cardoso Sandra S, Li Jiani J et al.

The introduction of potent, well-tolerated direct-acting antivirals (DAAs) has transformed hepatitis C virus (HCV) therapy and spurred global elimination efforts. However, the extensive genetic diversity of HCV may affect antiviral efficacy, particularly in low and middle-income regions where limited data currently exist. Using samples from the ACTG A5360 (MINMON) trial, which evaluated a minimal-monitoring strategy with 12 weeks of sofosbuvir/velpatasvir (SOF/VEL) across five countries, we characterized rare and novel HCV subtypes and assessed baseline resistance-associated substitutions (RASs) and treatment response. Genotype/subtype assignments were obtained by NS5B short-fragment sequencing and confirmed through next-generation and whole-genome sequencing. Among 399 participants, 389 (97.5%) were successfully genotyped; whole-genome sequencing in unresolved genotypes identified several provisional novel genotype 4 subtypes and a putative new genotype 7 subtype (7c). Despite the presence of baseline NS5A RASs, all participants with initially unsubtyped infections achieved sustained virologic response (SVR12). Reduced SVR was observed primarily among genotype 3b infections (78%), consistent with prior data linking A30K + L31M RASs to decreased NS5A inhibitor susceptibility. Overall, SOF/VEL achieved high SVR across genotypes, including rare and novel subtypes. These findings underscore both the increased recognition of global HCV genetic diversity and the robust performance of pangenotypic DAA regimens, supporting universal adoption of simplified treatment strategies, as proposed by the MINMON trial, towards HCV elimination. Trial Registration: ClinicalTrials.gov, NCT03512210.

PMID 42922282
阅读全文 →
PubMedBioinformatics (Oxford, England)2026-10-25

BioHarness: Substrate-Aware Evidence Assembly for Biomedical Question Answering across Literature, Knowledge Bases, and Biological Atlases.

Xiao Meng M, Qin Chuan C, Chen Jinmiao J, Cheng Yihang Y et al.

Biomedical question answering often requires evidence beyond topically retrieved literature, including gene alias resolution, database identifier normalization, and atlas-derived biological measurements. However, existing retrieval-augmented generation (RAG) systems typically follow a fixed workflow and lack an explicit mechanism for deciding when retrieved text is sufficient, when biomedical entity mapping is needed, or when executable evidence assembly over structured measurements should be invoked. This motivates a substrate-aware large language model (LLM) harness that selectively assembles sufficient evidence by combining literature retrieval, biomedical entity mapping, and access to atlas-derived measurements. We introduce BioHarness, an LLM harness for staged biomedical evidence assembly across literature retrieval, biomedical entity-mapping resources, and atlas-derived structured measurements. Across 22,123 biomedical QA items spanning seven answer formats, BioHarness improves the pooled score from 62.2 to 67.2 over the strongest baseline. Ablations, case studies, and backbone-scaling analyses show that these gains arise from repairing evidence-substrate mismatches through reranking, entity grounding, and structured measurement access, rather than from indiscriminately invoking more reasoning steps, retrieving additional literature, or relying on a particular answer-model scale. Comparisons with the frontier models and harness show that BioHarness, despite using an open-weight backbone with only 3B active parameters, approaches frontier-level performance on selected literature QA tasks and outperforms frontier harnesses without web access on biomedical identifier and locus lookup.

PMID 42924887
阅读全文 →
PubMedKidney international reports2026-10-25

Clinical Trial of Tolvaptan in Pediatric ADPKD: Two-Year, Open-Label Extension.

Mekahli Djalila D, Guay-Woodford Lisa M LM, Cadnapaphornchai Melissa A MA, Greenbaum Larry A LA et al.

Tolvaptan is indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) at increased risk of rapid progression. Pharmacodynamic activity and acceptable safety and tolerability were demonstrated in a 1-year, randomized, placebo-controlled trial in children and adolescents with ADPKD (Phase A of a 2-part, phase-3b study [NCT02964273]). Here, the 2-year, open-label extension (Phase B) is reported. Phase A participants could enter Phase B if they had not experienced adverse events requiring discontinuation. All Phase B participants received tolvaptan, titrated based on body weight and tolerability. Outcomes included safety, tolerability, kidney function, height-adjusted total kidney volume (htTKV), and health-related quality of life (HRQoL). Of 84 Phase A completers, 81 enrolled in Phase B. No liver enzyme elevations observed in either phase met criteria for drug-induced liver injury. The previous placebo group experienced more aquaresis-related (48.7% vs. 14.3%) and dehydration-related (28.2% vs. 14.3%) adverse events than the previous tolvaptan group in Phase B. Tolerability was favorable, with HRQoL outcomes indicating high functioning in both the trial phases. Estimated glomerular filtration rate (eGFR) remained stable in the tolvaptan arm and decreased in the placebo arm of Phase A (annual slope in ml/min per 1.73 m2 of 2.4 and -2.2, respectively [P = 0.04]), with similar slopes of decline for both arms of Phase B (-1.3 in the prior tolvaptan arm and -2.1 in the prior placebo arm [P = 0.54]). htTKV growth was slowest during the first year of tolvaptan treatment. Tolvaptan-related safety and overall HRQoL remained favorable, and kidney function was stable in this 2-year extension. The slowest htTKV growth occurred during year 1 of tolvaptan treatment.

PMID 42923342
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AS0-3B